JP2007508301A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508301A5
JP2007508301A5 JP2006533949A JP2006533949A JP2007508301A5 JP 2007508301 A5 JP2007508301 A5 JP 2007508301A5 JP 2006533949 A JP2006533949 A JP 2006533949A JP 2006533949 A JP2006533949 A JP 2006533949A JP 2007508301 A5 JP2007508301 A5 JP 2007508301A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
tetrahydro
benzyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533949A
Other languages
English (en)
Japanese (ja)
Other versions
JP4773969B2 (ja
JP2007508301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030907 external-priority patent/WO2005037796A1/en
Publication of JP2007508301A publication Critical patent/JP2007508301A/ja
Publication of JP2007508301A5 publication Critical patent/JP2007508301A5/ja
Application granted granted Critical
Publication of JP4773969B2 publication Critical patent/JP4773969B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533949A 2003-10-08 2004-10-07 脂質代謝異常の治療ための化合物及び方法 Expired - Fee Related JP4773969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50973603P 2003-10-08 2003-10-08
US60/509,736 2003-10-08
PCT/US2004/030907 WO2005037796A1 (en) 2003-10-08 2004-10-07 Compounds and methods for treating dyslipidemia

Publications (3)

Publication Number Publication Date
JP2007508301A JP2007508301A (ja) 2007-04-05
JP2007508301A5 true JP2007508301A5 (enExample) 2011-05-19
JP4773969B2 JP4773969B2 (ja) 2011-09-14

Family

ID=34465112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533949A Expired - Fee Related JP4773969B2 (ja) 2003-10-08 2004-10-07 脂質代謝異常の治療ための化合物及び方法

Country Status (25)

Country Link
US (1) US7749992B2 (enExample)
EP (2) EP2098512A1 (enExample)
JP (1) JP4773969B2 (enExample)
KR (1) KR20060085675A (enExample)
CN (1) CN1863778A (enExample)
AT (1) ATE442358T1 (enExample)
AU (1) AU2004282101A1 (enExample)
BR (1) BRPI0414186A (enExample)
CA (1) CA2537942A1 (enExample)
CY (1) CY1110537T1 (enExample)
DE (1) DE602004023100D1 (enExample)
DK (1) DK1670768T3 (enExample)
EA (1) EA200600737A1 (enExample)
EC (1) ECSP066484A (enExample)
ES (1) ES2332051T3 (enExample)
HR (1) HRP20090581T1 (enExample)
IL (1) IL173819A0 (enExample)
MA (1) MA28268A1 (enExample)
MX (1) MXPA06003927A (enExample)
NO (1) NO20062074L (enExample)
PL (1) PL1670768T3 (enExample)
PT (1) PT1670768E (enExample)
SI (1) SI1670768T1 (enExample)
WO (1) WO2005037796A1 (enExample)
ZA (1) ZA200602888B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433984T1 (de) * 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
CA2570688A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
CN103833636B (zh) * 2014-03-31 2015-09-02 武汉武药制药有限公司 一种莫扎伐普坦中间体的合成方法
EP3328835B1 (en) * 2015-07-31 2022-10-12 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2018155260A1 (ja) * 2017-02-23 2018-08-30 株式会社Ihi Ohラジカル検出プローブ、ohラジカル測定装置、および、ohラジカル測定方法
CN113195475A (zh) 2018-10-24 2021-07-30 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法
CN117088814A (zh) * 2023-02-16 2023-11-21 烟台大学 一种三氟甲硫化氮杂-8/9元环化合物的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
TW270927B (enExample) 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5484783A (en) 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
DK0765314T3 (da) 1994-06-15 2003-08-25 Otsuka Pharma Co Ltd Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
GB9523526D0 (en) 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
JPH09214746A (ja) 1996-02-02 1997-08-15 Ricoh Co Ltd 画像出力システム及び画像形成装置
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6333349B1 (en) 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Fo−5637a物質及びb物質並びにそれらの製造法
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US6664522B2 (en) * 2000-03-30 2003-12-16 Homer L. Spencer Method and apparatus for sealing multiple casings for oil and gas wells
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DK1383734T3 (da) 2001-04-30 2006-05-15 Pfizer Prod Inc Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater
HUP0400263A2 (hu) 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
JP2005522424A (ja) 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
ATE493456T1 (de) 2002-07-01 2011-01-15 Cytec Surface Specialties Sa Wasserverdünnbare polymervorläufer sowie herstellung und verwendung davon
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
EP1601655A2 (en) 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005033082A2 (en) 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
CA2570688A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Similar Documents

Publication Publication Date Title
EP3445749B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
AU2013296627C9 (en) Deuterated ibrutinib
CA3119656A1 (en) Macrocyclic compounds and their use in the treatment of disease
ES2445536T3 (es) Derivados de la pirazina y su uso en el tratamiento de trastornos neurológicos
JP2024522292A (ja) ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
CA3164134A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
AU2019310508B2 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
CA3190610A1 (en) Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
JP2011522843A (ja) 新規なカリウムチャンネルブロッカー及びその使用
JP5822840B2 (ja) 眼疾患処置薬
JP6042331B2 (ja) プロテアソーム活性を向上させる三環系化合物
JP7044392B2 (ja) マラリアの治療のための化合物及び方法
EP4406616A2 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
BRPI0708331A2 (pt) compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4
JP2007508301A5 (enExample)
CN101247807A (zh) 噻唑化合物及使用方法
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
CA3256658A1 (en) BICYCLE-DERIVED PARP INHIBITOR AND ITS USE
WO2017040877A1 (en) Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
JP2005527518A (ja) 新規なカルコン(chalcone)誘導体とその使用
CA3039070A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
UA124672C2 (uk) Гетероциклічні похідні пролінаміду
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ